Related Experiment Video
Updated: Oct 20, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
The Legislative Approach and System Improvement of China's Compulsory Licensing for Drug Patents
Zhang Cao1, Yichao Chen2, Wenjie Jiang1
1School of Law, Zhejiang University of Finance and Economics, Hangzhou, Zhejiang Province, People's Republic of China.
Abstract:
Compulsory licensing for drug patents is of great significance to ensure the accessibility of drugs. Although the development of China's compulsory licensing system for drug patents has been gradually improved, there are still problems. For example, the scope of the object is not realistic, the setting of the initiating subject is unreasonable, the reasons for issuance are not clear, the duration and scope of the license are not refined, and the provisions on the exploitation fee are missing. Consequently, in order to improve China's compulsory licensing system for drug patents, it is necessary to expand reasonably the scope of the object, remove the restrictions on the initiating subject, adjust the initiating rights of different subjects, determine the duration and scope of the license and the applicability of the hearing on a case-by-case basis, and determine a reasonable exploitation fee by taking into account the national income, patent cost, market share and other factors, in consideration of the flexibly international norms and the actual situation in China.
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Nomenclature
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
FDA Approved Drugs: Changes to Approved Drugs

